Prokarium key facts
as of Oct 2026- Operator of a biopharmaceutical company intended for developing bacterial immunotherapies for cancer.
- Prokarium is valued at approximately $109.4M as of Oct 2026 (last reported valuation).
- It has raised $88.8M; the latest was Later Stage VC ($6.3M) in Dec 2025.
- Notable investors include Innovate UK, Korea Investment Partners, London & Partners., British Business Bank, Wellcome Trust — 12 tracked in total.
- Status: Privately Held (backing).
Prokarium's last reported valuation, Feb 2023. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch Prokarium: the Monday email on marks, rounds and moves
Prokarium funding rounds
No funding rounds for Prokarium are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Prokarium
12+Prokarium valuation
Prokarium's last reported valuation was $109 million in Feb 2023. No priced round, secondary trade or fund mark has surfaced since.
Prokarium investors
12 investors are on record for Prokarium, including Innovate UK, Korea Investment Partners, London & Partners. and British Business Bank.
About Prokarium
Operator of a biopharmaceutical company intended for developing bacterial immunotherapies for cancer. The company's proprietary technology naturally homes to tumors, stimulates anti-tumor immune responses, and can be programmed to deliver therapeutic agents directly inside the tumor microenvironment, targeting non-muscle invasive bladder cancer, enabling the healthcare industry to treat patients with cancers whose tumors resist or do not respond well to current immunotherapies.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2012
- Employees
- 18
- Website
- prokarium.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.